Results 1 to 10 of about 75,178 (323)

A comparison of intramuscular (Zimhi) and intranasal naloxone (Narcan) in reversal of fentanyl-induced apnea: a randomized, crossover, open-label trial [PDF]

Nature Communications
Severe opioid-induced respiratory depression (OIRD) can be treated with intranasal (IN) or intramuscular (IM) naloxone. It is relevant to compare their efficacy and determine the optimal strategy to restore breathing following OIRD.
Maarten A. van Lemmen, Monique van Velzen, Elise Y. Sarton, Albert Dahan, Marieke Niesters, Rutger M. van der Schrier   +5 more
doaj   +2 more sources

Bridging the Gap Between Knowledge and Practices Pertaining to Naloxone Use: A Single-Institution Experience in North Carolina [PDF]

Journal of Patient-Centered Research and Reviews
Naloxone is a life-saving medication for opioid overdose, which claims many lives annually. This study investigated provider attitudes about, beliefs about, and barriers to naloxone use to inform an increase in provider prescription of naloxone.
Michael S. Argenyi, Gisele Bailey, Christopher J. McLouth, Erin Barnes, Candice J. McNeil   +4 more
doaj   +2 more sources

Optimizing naloxone distribution to prevent opioid overdose fatalities: results from piloting the Systems Analysis and Improvement Approach within syringe service programs

BMC Health Services Research, 2023
Background Opioid overdose fatalities are preventable with timely administration of naloxone, an opioid antagonist, during an opioid overdose event. Syringe service programs have pioneered naloxone distribution for potential bystanders of opioid overdose.
Sheila V. Patel, Lynn D. Wenger, Alex H. Kral, Kenneth Sherr, Anjuli D. Wagner, Peter J. Davidson, Barrot H. Lambdin   +6 more
doaj   +1 more source

Practical implications of naloxone knowledge among suburban people who use opioids

Harm Reduction Journal, 2021
Background Naloxone distribution programs have been a cornerstone of the public health response to the overdose crisis in the USA. Yet people who use opioids (PWUO) continue to face a number of barriers accessing naloxone, including not knowing where it ...
Kristin E. Schneider, Glenna J. Urquhart, Saba Rouhani, Ju Nyeong Park, Miles Morris, Sean T. Allen, Susan G. Sherman   +6 more
doaj   +1 more source

Overdose education and naloxone distribution program design informed by people who use drugs and naloxone distributors

Preventive Medicine Reports, 2023
People who use drugs (PWUD) are the most directly affected by the overdose epidemic. However, they are not often targets of overdose education and naloxone distribution (OEND) programs.
Michael Enich, Rachel Flumo, Stephanie Campos, Netanya Flores, Nora Sullivan, Jenna Mellor, Caitlin O'Neill, Amesika N. Nyaku   +7 more
doaj   +1 more source

Adverse events related to bystander naloxone administration in cases of suspected opioid overdose in British Columbia: An observational study.

PLoS ONE, 2021
IntroductionTake-Home Naloxone programs have been introduced across North America in response to rising opioid overdose deaths. There is currently limited real-world data on bystander naloxone administration, overdose outcomes, and evidence related to ...
Amina Moustaqim-Barrette, Kristi Papamihali, Sierra Williams, Max Ferguson, Jessica Moe, Roy Purssell, Jane A Buxton   +6 more
doaj   +2 more sources

Pharmacy Students’ Perceptions and Stigma Surrounding Naloxone Use in Patients with Opioid Use Disorder: A Mixed Methods Evaluation

Pharmacy, 2020
Pharmacists represent a key group of healthcare professionals that can increase awareness and destigmatize naloxone use. The objective of this study was to investigate pharmacy student perceptions of the use, dispensing, and stigma surrounding naloxone ...
Alina Cernasev, Michael P. Veve, Taylor Talbott, Elizabeth A. Hall, Kenneth C. Hohmeier   +4 more
doaj   +1 more source

Investigating Community Pharmacy Take Home Naloxone Dispensing during COVID-19: The Impact of One Public Health Crisis on Another

Pharmacy, 2021
A recent report found that the number of opioid-related deaths in Ontario in the first 15 weeks of the COVID-19 pandemic was 38.2% higher than in the 15 weeks before the pandemic.
George Daskalakis, Ashley Cid, Kelly Grindrod, Michael A. Beazely   +3 more
doaj   +1 more source

Harm reduction behaviors are associated with carrying naloxone among patients on methadone treatment

Harm Reduction Journal, 2023
Background Despite the widespread availability of naloxone, US opioid overdose rates continue to rise. The “Cascade of Care” (CoC) is a public health approach that identifies steps in achieving specific outcomes and has been used to identify gaps in ...
Zofia Kozak, Daniel Ciccarone, Johannes Thrul, Thomas O. Cole, Alexander L. Pappas, Aaron D. Greenblatt, Christopher Welsh, Mark Yoon, Donald Gann, E. Erin Artigiani, Eric D. Wish, Annabelle M. Belcher   +11 more
doaj   +1 more source

Patient perspectives on naloxone receipt in the emergency department: a qualitative exploration

Harm Reduction Journal, 2022
Background Emergency departments (EDs) are important venues for the distribution of naloxone to patients at high risk of opioid overdose, but less is known about patient perceptions on naloxone or best practices for patient education and communication ...
Margaret Lowenstein, Hareena K. Sangha, Anthony Spadaro, Jeanmarie Perrone, M. Kit Delgado, Anish K. Agarwal   +5 more
doaj   +1 more source